News
INDV
32.52
-1.36%
-0.45
NRx Pharmaceuticals names Glenn Tyson as first chief commercial officer
PUBT · 3d ago
Weekly Report: what happened at INDV last week (0406-0410)?
Weekly Report · 3d ago
Assessing Indivior (INDV) Valuation After New SUBLOCADE Study In Correctional Healthcare
Simply Wall St · 3d ago
IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results
NASDAQ · 5d ago
Could Indivior (INDV) Turn Correctional Staffing Efficiencies Into a Durable Competitive Edge?
Simply Wall St · 6d ago
Indivior to report Q1 financial results, host webcast update
Reuters · 04/09 11:03
Press Release: Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
Dow Jones · 04/09 11:00
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
Barchart · 04/09 06:00
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
NASDAQ · 04/06 15:10
Weekly Report: what happened at INDV last week (0330-0403)?
Weekly Report · 04/06 09:25
Assessing Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After New SUBLOCADE Cost Savings Evidence In Corrections Settings
Simply Wall St · 04/04 01:25
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
NASDAQ · 04/02 14:00
Did Potential Jail Staffing Efficiencies From SUBLOCADE® Just Shift Indivior Pharmaceuticals' (INDV) Investment Narrative?
Simply Wall St · 04/02 09:24
Indivior model shows monthly Sublocade cuts jail MOUD staffing time versus methadone, oral buprenorphine
Reuters · 03/31 22:12
New Model Puts Indivior’s SUBLOCADE Correctional Opportunity In Focus
Simply Wall St · 03/31 16:11
Zacks.com featured highlights include Indivior, Ciena and Ultra Clean
NASDAQ · 03/31 09:22
Indivior: Still Attractive After FY25 Earnings Beat
Seeking Alpha · 03/30 17:23
Is It Time To Reassess Indivior Pharmaceuticals (INDV) After Its 200% One Year Surge?
Simply Wall St · 03/30 13:05
Weekly Report: what happened at INDV last week (0323-0327)?
Weekly Report · 03/30 09:25
Indivior announces annual shareholder meeting; FY2025 total net revenue rises to $1.2 billion
Reuters · 03/27 10:07
More
Webull provides a variety of real-time INDV stock news. You can receive the latest news about Indivior Pharmaceuticals Inc. through multiple platforms. This information may help you make smarter investment decisions.
About INDV
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.